Spots Global Cancer Trial Database for Rollover Study Of Lapatinib In Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Rollover Study Of Lapatinib In Cancer Patients
Official Title: An Open Label, Phase 1b Rollover Study to Assess the Long-Term Safety Profile of Lapatinib (GW572016) in Cancer Patients.
Study ID: NCT00169533
Conditions
Interventions
Study Description
Brief Summary: The EGF19060 study is a rollover study to evaluate the long term safety of lapatinib and to provide lapatinib to patients who had a positive response in previous lapatinib studies until lapatinib is available pending FDA approval.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
GSK Investigational Site, Indianapolis, Indiana, United States
GSK Investigational Site, Detroit, Michigan, United States
GSK Investigational Site, Lebanon, New Hampshire, United States
GSK Investigational Site, Albuquerque, New Mexico, United States
GSK Investigational Site, Chapel Hill, North Carolina, United States
GSK Investigational Site, Durham, North Carolina, United States
GSK Investigational Site, Cleveland, Ohio, United States
GSK Investigational Site, Philadelphia, Pennsylvania, United States
GSK Investigational Site, Nashville, Tennessee, United States
GSK Investigational Site, San Antonio, Texas, United States
GSK Investigational Site, Edmonton, Alberta, Canada
GSK Investigational Site, Tel Aviv, , Israel
Contact Details
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
